Skip to main content

Table 2 Efficacy results at year 4 in the telbivudine-treated Taiwanese population of the GLOBE trial

From: Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24

 

All ITT patients

Patients with HBV DNA level <300 copies/mL at Week 24

Characteristic

HBeAg-positive (n = 16)

HBeAg-negative (n = 25)

HBeAg-positive (n = 7)

HBeAg-negative (n = 16)

HBV DNA level

    

<300 copies/mL, n (%)

8/16 (50.0)

19/25 (76.0)

7/7 (100.0)

11/16 (78.3)

ALT normalization, n (%)

9/16 (56.3)

20/24 (83.0)

5/7 (71.4)

11/15 (86.4)

HBeAg loss, n (%)

6/16 (37.5)

NA

6/7 (85.7)

NA

HBeAg seroconversion, n (%)

4/16 (25)

NA

4/7 (57.1)

NA

Resistance, n (%)

7/16 (43.8)

3/24 (12.5)

0/7 (0.0)

2/23 (8.7)